$KACL
Kairous Acquisition Corp. Ltd Stock $kacl

$kacl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017380 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$100.0K	$213.8K	$70.14K
YoY Change	-7.76%	204.79%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$100.0K	$213.8K	$70.14K
YoY Change	-7.76%	204.78%
Operating Profit		-$213.8K	-$70.14K
YoY Change		204.79%
Interest Expense	$270.0K	$230.9K	$7.920K
YoY Change	153.78%	2815.53%
% of Operating Profit
Other Income/Expense, Net		$230.9K	$7.920K
YoY Change		2815.53%
Pretax Income	$160.0K	$17.13K	-$62.22K
YoY Change	-8060.2%	-127.53%
Income Tax
% Of Pretax Income
Net Earnings	$160.0K	$17.13K	-$62.22K
YoY Change	-8060.2%	-127.54%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00	-$0.01
Diluted Earnings Per Share	$0.04	$0.00	-$6.225K
COMMON SHARES
Basic Shares Outstanding	4.436M shares	4.436M shares	9.995M shares
Diluted Shares Outstanding		4.436M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.00K	$123.3K	$535.0K
YoY Change	-91.72%	-76.95%
Cash & Equivalents	$39.36K	$123.3K	$535.0K
Short-Term Investments
Other Short-Term Assets	$70.00K	$153.7K	$126.0K
YoY Change	-36.43%	21.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$112.2K	$277.0K	$661.0K
YoY Change	-81.09%	-58.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$22.80M	$22.41M	$78.79M
YoY Change	-71.1%	-71.55%
Other Assets	$0.00	$0.00	$36.60K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$22.80M	$22.41M	$78.82M
YoY Change	-71.11%	-71.56%
TOTAL ASSETS
Total Short-Term Assets	$112.2K	$277.0K	$661.0K
Total Long-Term Assets	$22.80M	$22.41M	$78.82M
Total Assets	$22.91M	$22.69M	$79.49M
YoY Change	-71.18%	-71.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$120.0K	$218.8K	$7.000K
YoY Change	231.03%	3025.29%
Accrued Expenses	$0.00	$15.00K	$15.00K
YoY Change	-100.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.260M	$1.090M	$70.00K
YoY Change	1700.0%	1457.14%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.384M	$1.324M	$92.00K
YoY Change	1041.14%	1338.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.384M	$1.324M	$92.00K
Total Long-Term Liabilities	$2.730M	$2.730M	$2.730M
Total Liabilities	$4.114M	$4.054M	$2.822M
YoY Change	44.27%	43.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.002M	-$3.777M
YoY Change	79.2%
Common Stock	$235.00	$235.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.001M	-$3.777M	$76.66M
YoY Change
Total Liabilities & Shareholders Equity	$22.91M	$22.69M	$79.49M
YoY Change	-71.18%	-71.45%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$160.0K	$17.13K	-$62.22K
YoY Change	-8060.2%	-127.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$120.0K	-$308.0K	-$278.6K
YoY Change	130.72%	10.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$120.0K	-$360.0K	$0.00
YoY Change
Cash From Investing Activities	-$120.0K	-$360.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	150.0K	660.0K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-120.0K	-308.0K	-278.6K
Cash From Investing Activities	-120.0K	-360.0K	0.000
Cash From Financing Activities	150.0K	660.0K	0.000
Net Change In Cash	-90.00K	-7.950K	-278.6K
YoY Change	73.04%	-97.15%
FREE CASH FLOW
Cash From Operating Activities	-$120.0K	-$308.0K	-$278.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001865468
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2022Q2	KACL	Extension Loans ExtensionLoans		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	KACL	Deferred Underwriters Commissions Charged To Additional Paidin Capital In Connection With Public Offering DeferredUnderwritersCommissionsChargedToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
	KACL	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue		usd
CY2022Q2	KACL	Extension Loans ExtensionLoans		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Type DocumentType	10-Q
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2089816	shares
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41155
	dei	Entity Registrant Name EntityRegistrantName	Kairous Acquisition Corp. Limited
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Unit 9-3, Oval Tower @ Damansara
	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 685, Jalan Damansara
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60000
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Taman Tun Dr. Ismail
	dei	Entity Address City Or Town EntityAddressCityOrTown	Kuala Lumpur
	dei	Entity Address Country EntityAddressCountry	MY
	dei	City Area Code CityAreaCode	+603
	dei	Local Phone Number LocalPhoneNumber	7733 9340
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4435959	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123327	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	482965	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	153689	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	110116	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	277016	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	593081	usd
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22414675	usd
CY2022Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	78894512	usd
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	25363	usd
CY2023Q1	us-gaap	Assets Assets	22691691	usd
CY2022Q2	us-gaap	Assets Assets	79512956	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	218774	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36250	usd
CY2023Q1	KACL	Accrued Offering Costs Current AccruedOfferingCostsCurrent	15000	usd
CY2022Q2	KACL	Accrued Offering Costs Current AccruedOfferingCostsCurrent	15000	usd
CY2023Q1	KACL	Extension Loans ExtensionLoans	720000	usd
CY2023Q1	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	370000	usd
CY2022Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	70000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1323774	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	121250	usd
CY2023Q1	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2022Q2	KACL	Deferred Underwriting Commission Non Current DeferredUnderwritingCommissionNonCurrent	2730000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4053774	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2851250	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7800000	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	22414675	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	78894512	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	2089816	shares
CY2022Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	7800000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	235	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3776993	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2233041	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3776758	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22691691	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79512956	usd
CY2023Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	14969	usd
CY2022Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	15000	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	44969	usd
	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	17419	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	198807	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55138	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	779006	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	73889	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	213776	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	70138	usd
	us-gaap	Operating Expenses OperatingExpenses	823975	usd
	us-gaap	Operating Expenses OperatingExpenses	91308	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-213776	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-70138	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-823975	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-91308	usd
CY2023Q1	KACL	Interest Income InterestIncome	4	usd
CY2022Q1	KACL	Interest Income InterestIncome	20	usd
	KACL	Interest Income InterestIncome	23	usd
	KACL	Interest Income InterestIncome	20	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	230906	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	7900	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	1112564	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	8132	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230910	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7920	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1112587	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8152	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	17134	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62218	usd
	us-gaap	Net Income Loss NetIncomeLoss	288612	usd
	us-gaap	Net Income Loss NetIncomeLoss	-83156	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4435959	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9995250	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7687013	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5160246	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2232806	usd
CY2022Q3	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-355581	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	159284	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2429103	usd
CY2022Q4	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-886077	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	112194	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3203986	usd
CY2023Q1	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-590906	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	17134	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3776758	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3776758	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18695	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5724	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	12971	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	7729883	usd
CY2021Q4	KACL	Stock Issued During Period Value Sale Of Private Placement Units Net Of Allocated Offering Costs StockIssuedDuringPeriodValueSaleOfPrivatePlacementUnitsNetOfAllocatedOfferingCosts	3532263	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	341230	usd
CY2021Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-13655157	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-15214	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2054064	usd
CY2022Q1	KACL	Temporary Equity Remeasurement To Redemption Value Adjustment TemporaryEquityRemeasurementToRedemptionValueAdjustment	-8132	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62218	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2124414	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2124414	usd
	us-gaap	Net Income Loss NetIncomeLoss	288612	usd
	us-gaap	Net Income Loss NetIncomeLoss	-83156	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	1112564	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	8132	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43573	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	121013	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25363	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	36595	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	182524	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35701	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-659638	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-213195	usd
	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	720000	usd
	KACL	Cash Deposited Into Trust Account CashDepositedIntoTrustAccount	78780000	usd
	KACL	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	58312401	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	57592401	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-78780000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	76440100	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3571430	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	58312401	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	720000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	300000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	70000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	553352	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57292401	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79528178	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-359638	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	534983	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	482965	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123327	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	534983	usd
	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	1832564	usd
	KACL	Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	8132	usd
	KACL	Deferred Underwriters Commissions Charged To Additional Paidin Capital In Connection With Public Offering DeferredUnderwritersCommissionsChargedToAdditionalPaidinCapitalInConnectionWithPublicOffering	2730000	usd
	KACL	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	13655197	usd
CY2021Q4	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	4843252	usd
CY2021Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1559900	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2730000	usd
CY2021Q4	KACL	Other Offering Costs OtherOfferingCosts	553352	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2730000	usd
	KACL	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
	KACL	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
	KACL	Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent	0.15	pure
	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
	KACL	Redemption Period Upon Closure RedemptionPeriodUponClosure	P12M
	KACL	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
	KACL	Maximum Net Interest To Pay Dissolution Expenses MaximumNetInterestToPayDissolutionExpenses	100000	usd
CY2023Q1	KACL	Working Capital Deficit WorkingCapitalDeficit	1046758	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123327	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zuzxqQBVTBU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zKHKri7KbDe7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Cash	123327	usd
CY2022Q2	us-gaap	Cash Cash	482965	usd
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	22400000	usd
CY2022Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	78900000	usd
	KACL	Offering Costs Associated With Initial Public Offering OfferingCostsAssociatedWithInitialPublicOffering	<p id="xdx_842_ecustom--OfferingCostsAssociatedWithInitialPublicOffering_zcqViuJwTHB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zuMiLiBpC2r">Offering Costs associated with the Initial Public Offering</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, <i>“Expenses of Offering.”</i> Offering costs of $<span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_c20220701__20230331__us-gaap--IncomeStatementLocationAxis__custom--OtherCostMember_zVfgTUrmw3Vg" title="Transaction costs">894,582</span> consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $<span id="xdx_900_ecustom--UnderwriterFee_c20220701__20230331_zObVkhkdgmL7" title="Underwriter fees">4,289,900</span> (or $<span id="xdx_90D_eus-gaap--PaymentsForUnderwritingExpense_c20220701__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zAy259foqNpl" title="Underwriting fees">1,559,900</span> paid in cash upon the closing of the Initial Public Offering and a deferred fee of $<span id="xdx_90C_eus-gaap--OtherUnderwritingExpense_c20220701__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--DeferredUnderwritingCommissionsMember_zddZtKnJvLva" title="Deferred underwriter fees">2,730,000</span>), were charged to stockholders’ equity upon completion of the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	KACL	Underwriter Fee UnderwriterFee	4289900	usd
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
CY2023Q1	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	2089816	shares
CY2022Q2	KACL	Temporary Equity Subject To Possible Redemption TemporaryEquitySubjectToPossibleRedemption	7800000	shares
CY2023Q1	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	22414675	usd
CY2022Q2	KACL	Temporary Equity Carrying Amount TemporaryEquityCarryingAmount	78894512	usd
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
CY2023Q1	KACL	Redemption Of Ordinary Share RedemptionOfOrdinaryShare	-58312401	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zyAxLwqzCea2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z6qF16tlQbR8">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20230331_z3lB9WhYhqF2" title="Cash FDIC insured amount">250,000</span>. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	370000	usd
CY2022Q2	KACL	Working Capital Loans Sponsor WorkingCapitalLoansSponsor	70000	usd
CY2023Q1	KACL	Extension Loans ExtensionLoans	720000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1125000	shares
	KACL	Percentage Of Underwriting Discountfee PercentageOfUnderwritingDiscountfee	0.20
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1725000	usd
	KACL	Deferred Fees Per Share DeferredFeesPerShare	0.35
	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	59900	usd
	KACL	Deferred Purchase Fee DeferredPurchaseFee	100	usd
	KACL	Deferred Underwriting Fee DeferredUnderwritingFee	105000	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	39000	shares
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	341230	usd
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	26732672	shares
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	270000000	usd
	KACL	Stock Issued During Period Value New Issuess StockIssuedDuringPeriodValueNewIssuess	26465345	shares
	KACL	Number Of Shares On Hold Back By Purchaser NumberOfSharesOnHoldBackByPurchaser	267327	shares
	KACL	Number Of Additional Shares Issued Upon Contingent Post Closing Earnout Consideration NumberOfAdditionalSharesIssuedUponContingentPostClosingEarnoutConsideration	5400000	shares
CY2023Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	5600000	usd
CY2023Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.10
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2346143	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2346143	shares
CY2023Q1	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	2089816	shares
CY2022Q2	KACL	Shares Subject To Mandatory Redemption Settlement Terms Shares SharesSubjectToMandatoryRedemptionSettlementTermsShares	7800000	shares
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	5710184	shares
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	58312401	usd
	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Description SharesSubjectToMandatoryRedemptionSettlementTermsDescription	if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders;
	KACL	Shares Issuable Upon Conversion As Percentage On Shares Outstanding After Conversion SharesIssuableUponConversionAsPercentageOnSharesOutstandingAfterConversion	0.098	pure

Files In Submission

Name	View Source	Status
kacl-20230331_def.xml	Edgar Link	unprocessable
kacl-20230331_cal.xml	Edgar Link	unprocessable
0001493152-23-017380-index-headers.html	Edgar Link	pending
0001493152-23-017380-index.html	Edgar Link	pending
0001493152-23-017380.txt	Edgar Link	pending
0001493152-23-017380-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q.htm	Edgar Link	pending
kacl-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
kacl-20230331_lab.xml	Edgar Link	unprocessable
kacl-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KACL
Kairous Acquisition Corp. Ltd Stock $kacl

2023 Q2 Form 10-Q Financial Statement

#000149315223017380 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACL Kairous Acquisition Corp. Ltd Stock $kacl

2023 Q2 Form 10-Q Financial Statement

#000149315223017380 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KACL
Kairous Acquisition Corp. Ltd Stock $kacl